← Back to Search

Blood Product

RBC Transfusion from male donor for Blood Transfusion (iTADS Trial)

Phase 4
Waitlist Available
Led By Michaël Chassé
Research Sponsored by Ottawa Hospital Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
All patients (excluding neonates) requiring one or more allogeneic RBC transfusions for the treatment of anemia will be included.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

iTADS Trial Summary

This trial will help determine if male donor blood leads to a greater benefit for transfusion recipients compared to female donor blood.

iTADS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

iTADS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Health system costs
Infection rates
Length of hospital stay
+7 more

iTADS Trial Design

2Treatment groups
Active Control
Group I: RBC Transfusion from male donorActive Control1 Intervention
For the treatment of anemia
Group II: RBC Transfusion from female donorActive Control1 Intervention
For the treatment of anemia

Find a Location

Who is running the clinical trial?

Ottawa Hospital Research InstituteLead Sponsor
559 Previous Clinical Trials
2,776,702 Total Patients Enrolled
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,333 Previous Clinical Trials
25,738,508 Total Patients Enrolled
Canadian Blood ServicesOTHER
20 Previous Clinical Trials
11,789 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~1362 spots leftby Mar 2025